Establishing a Tumor Registry of Patients With Mesonephric-like Adenocarcinoma (MLA)

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06377527

Enrollment

2000

Registered

2024-04-22

Start date

2024-07-10

Completion date

2037-12-28

Last updated

2026-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mesonephric-like Adenocarcinoma

Brief summary

To develop a database of medical information about patients with MLA in an effort to increase our understanding of the characteristics of MLA, which is the rarest form of endometrial carcinoma.

Detailed description

Primary Objectives 1\. To collect data on participants characteristics, disease characterization, pathology and molecular data, treatment, and outcomes for participants with gynecologic mesonephric-like adenocarcinoma (MLA). Secondary Objectives 1. To organize clinical information to support multifaceted queries of participant characteristics, treatment, and disease outcome data and to facilitate correlation of these characteristics with participant outcome. 2. To have a single data repository kept on a secure platform that will integrate clinical information and research findings and serve as an archive for future research.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

OTHER

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Adult patients over the age of 18. 2. Patients with a diagnosis of gynecologic mesonephric-like adenocarcinoma (MLA), mesonephric adenocarcinoma (MA), mesonephric carcinosarcoma, or mesonephric-like carcinosarcomas. 3. For patients who provide consent, they must speak and/or read English or Spanish.

Exclusion criteria

1. Patients with other subtypes of EACs. 2. Patients who are considered cognitively impaired. Assessment will be obtained based on their need of a Legally Authorized Representative.

Design outcomes

Primary

Measure	Time frame	Description
Tumor Registry	Through study completion; an average of 1 year	The goal of this data collection study is to develop a database (i.e. a registry/repository) of medical information about patients with MLA in an effort to increase our understanding of the characteristics of MLA, which is the rarest form of endometrial carcinoma.

Countries

United States

Contacts

CONTACTJeffrey How, MD

askmdanderson@mdanderson.org877-632-6789

PRINCIPAL_INVESTIGATORJeffrey How, MD

M.D. Anderson Cancer Center

Outcome results